2 hasil untuk "Michael Guth"
Menampilkan 1–2 · 0,18 detik · RSS
-
Artikel Jurnal
The highest clinical trial failure rate for any disease in modern medicine: How both amyloid- and non-amyloid-targeting therapies failed to alter disease course in Alzheimer's disease
Background: Alzheimer's disease drug development has produced a 99.6 percent failure rate for disease-modifying compounds (244 compounds tested 2002–2012, one regulatory approval; Cummings et al., 2014; Cummings, 2018)—the most sustained and costly therapeutic failure in the history of modern…
-
Artikel Jurnal
Alzheimer's disease in the Plasticene era: a clinicopathological update on the dual sequestration of amyloid and tau as hijacked innate immune responses
Background: The defining neuropathological hallmarks of Alzheimer's disease (AD)—amyloid-β (Aβ) plaques and tau neurofibrillary tangles (NFTs)—are now understood to exist along a continuum with brain aging, yet their fundamental trigger in sporadic disease remains enigmatic. The clinical failure of…